SCHEMBL1890214

SCHEMBL1890214

CN1CCC(Nc2cc(N3CCOCC3)ccc2C(=O)Nc2n[nH]c3c2CN(S(=O)(=O)c2cc(F)cc(F)c2)CC3(C)C)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 12/20 0.52
INSR P06213 12/20 0.52
ALK Q9UM73 12/20 0.52
NTRK1 P04629 5/20 0.52
NTRK3 Q16288 5/20 0.52
NTRK2 Q16620 5/20 0.52
AURKA O14965 2/20 0.52
AURKB Q96GD4 2/20 0.52
PLK4 O00444 1/20 0.52
DAPK3 O43293 1/20 0.52
JAK2 O60674 1/20 0.52
MAP4K4 O95819 1/20 0.52
ABL1 P00519 1/20 0.52
PRKCG P05129 1/20 0.52
LCK P06239 1/20 0.52
FYN P06241 1/20 0.52
CSF1R P07333 1/20 0.52
LYN P07948 1/20 0.52
RET P07949 1/20 0.52
MET P08581 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1886641 0.95 INSR (0.52) IGF1RINSRALKNTRK1NTRK3
SCHEMBL1888371 0.95 INSR (0.58) IGF1RINSRALKNTRK1NTRK3
SCHEMBL1885336 0.95 IGF1R (0.58) IGF1RINSRALKNTRK1NTRK3
SCHEMBL1889035 0.94 IGF1R (0.51) IGF1RINSRALKNTRK1NTRK3
SCHEMBL1892272 0.92 INSR (0.58) IGF1RINSRALKNTRK1NTRK3
SCHEMBL1886776 0.91 IGF1R (0.56) IGF1RINSRALKNTRK1NTRK3
SCHEMBL1888327 0.91 IGF1R (0.57) IGF1RINSRALKNTRK1NTRK3
SCHEMBL1894285 0.90 IGF1R (0.48) IGF1RINSRALKNTRK1NTRK3
SCHEMBL1896149 0.90 IGF1R (0.58) IGF1RINSRALKNTRK1NTRK3
SCHEMBL1893607 0.90 INSR (0.53) IGF1RINSRALKNTRK1NTRK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173659-B2 Substituted pyrazolo[4,3-C]pyridine derivatives active as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-05-08 US disclosed
US-20110230470-A1 SUBSTITUTED PYRAZOLO[4,3-C]PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-09-22 US disclosed
US-7947686-B2 Substituted pyrazolo[4,3-c]pyridine derivatives active as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-05-24 US disclosed
US-20090023745-A1 Substituted Pyrazolo[4,3-c]Pyridine Derivatives Active as Kinase Inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2009-01-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110230470-A1 SUBSTITUTED PYRAZOLO[4,3-C]PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS MAP3K3, MAP3K1, MAP3K19 IGF1R 760/4885INSR 922/4885ALK 517/4885
US-20090023745-A1 Substituted Pyrazolo[4,3-c]Pyridine Derivatives Active as Kinase Inhibitors MAP3K3, MAP3K1, MAP3K19 IGF1R 760/4885INSR 922/4885ALK 517/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.